Merck buys out IOmet, adding new immuno-oncology tech

John Carroll

has snagged Edinburgh-based for an undisclosed sum, a preclinical pipeline of therapies that target the IDO/TDO pathways that may help spur an immune system attack on cancer.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS